Mr Sanjeev Johar, CEO, Alere India
Medical experts from all over India, discussed the most up-to-date standards in clinical application of biomarkers for early diagnosis and better prognosis at the third edition of Alere Biomarker Conclave on October 5-6, 2013. Below are the details of eclusive interaction held by BioSpectrum with Mr Sanjeev Johar, CEO, Alere India, who spoke on various aspects of the industry.
Q: How important are the biomarkers for diagnostics?
Biomarkers have come to occupy an important place in our diagnostic procedures. They not only improve diagnostic accuracy, but also provide information about the present disease state, thereby aiding clinicians in deciding how aggressively the disease needs to be treated. We have been trying to create awareness about these vital investigative modalities by organizing the conclaves in various cities of India. This year in Gurgaon, the discussions at the conclave, focused on newer biomarkers and guidelines.
Q Please tell us about the medical devices market? What are the latest trends?
The growth of this industry has been close to $ 2 billion and is growing at 12-13 percent per annum. I agree with the most of the predicted reports that in next 3-5 years, this industry is expected to grow at a much faster rate and go upto $ 4-5 billion.